iBio (IBIO) Competitors

$1.55 -0.06 (-3.73%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$1.56 +0.01 (+0.39%)

As of 05/13/2026 07:59 PM Eastern

IBIO vs. VYGR, FENC, HRTX, RNAC, and NKTX

Should you buy iBio stock or one of its competitors? MarketBeat compares iBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iBio include Voyager Therapeutics (VYGR), Adherex Technologies (FENC), Heron Therapeutics (HRTX), Cartesian Therapeutics (RNAC), and Nkarta (NKTX). These companies are all part of the "pharmaceutical products" industry.

How does iBio compare to Voyager Therapeutics?

iBio (NASDAQ:IBIO) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

In the previous week, Voyager Therapeutics had 2 more articles in the media than iBio. MarketBeat recorded 7 mentions for Voyager Therapeutics and 5 mentions for iBio. iBio's average media sentiment score of 0.98 beat Voyager Therapeutics' score of 0.52 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Voyager Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

iBio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Voyager Therapeutics' return on equity of -55.97% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-64.97%	-54.58%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

iBio has higher earnings, but lower revenue than Voyager Therapeutics. iBio is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	140.04	-$18.38M	-$0.58	N/A
Voyager Therapeutics	$40.37M	6.21	-$119.72M	-$1.97	N/A

7.9% of iBio shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

iBio presently has a consensus price target of $4.75, suggesting a potential upside of 206.45%. Voyager Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 297.59%. Given Voyager Therapeutics' higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Voyager Therapeutics beats iBio on 9 of the 16 factors compared between the two stocks.

How does iBio compare to Adherex Technologies?

iBio (NASDAQ:IBIO) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

In the previous week, iBio had 3 more articles in the media than Adherex Technologies. MarketBeat recorded 5 mentions for iBio and 2 mentions for Adherex Technologies. iBio's average media sentiment score of 0.98 beat Adherex Technologies' score of 0.94 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

iBio has a net margin of 0.00% compared to Adherex Technologies' net margin of -22.62%. iBio's return on equity of -64.97% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-64.97%	-54.58%
Adherex Technologies	-22.62%	-183.18%	-15.31%

Adherex Technologies has higher revenue and earnings than iBio. Adherex Technologies is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	140.04	-$18.38M	-$0.58	N/A
Adherex Technologies	$44.64M	5.24	-$9.74M	-$0.34	N/A

7.9% of iBio shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

iBio presently has a consensus price target of $4.75, suggesting a potential upside of 206.45%. Adherex Technologies has a consensus price target of $14.80, suggesting a potential upside of 118.61%. Given iBio's stronger consensus rating and higher possible upside, equities research analysts clearly believe iBio is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17
Adherex Technologies	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

iBio beats Adherex Technologies on 10 of the 17 factors compared between the two stocks.

How does iBio compare to Heron Therapeutics?

iBio (NASDAQ:IBIO) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

iBio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

In the previous week, Heron Therapeutics had 4 more articles in the media than iBio. MarketBeat recorded 9 mentions for Heron Therapeutics and 5 mentions for iBio. iBio's average media sentiment score of 0.98 beat Heron Therapeutics' score of 0.13 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.9% of iBio shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 2.8% of iBio shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

iBio presently has a consensus price target of $4.75, suggesting a potential upside of 206.45%. Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 392.13%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17
Heron Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

iBio has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	140.04	-$18.38M	-$0.58	N/A
Heron Therapeutics	$154.90M	1.12	-$20.19M	-$0.18	N/A

iBio has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. iBio's return on equity of -64.97% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-64.97%	-54.58%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Summary

Heron Therapeutics beats iBio on 9 of the 17 factors compared between the two stocks.

How does iBio compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, iBio has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

In the previous week, Cartesian Therapeutics had 1 more articles in the media than iBio. MarketBeat recorded 6 mentions for Cartesian Therapeutics and 5 mentions for iBio. iBio's average media sentiment score of 0.98 beat Cartesian Therapeutics' score of 0.78 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cartesian Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cartesian Therapeutics currently has a consensus price target of $33.00, indicating a potential upside of 291.92%. iBio has a consensus price target of $4.75, indicating a potential upside of 206.45%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cartesian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

iBio has lower revenue, but higher earnings than Cartesian Therapeutics. iBio is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cartesian Therapeutics	$2.80M	88.35	-$130.30M	-$5.90	N/A
iBio	$400K	140.04	-$18.38M	-$0.58	N/A

iBio has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%
iBio	N/A	-64.97%	-54.58%

Summary

Cartesian Therapeutics beats iBio on 9 of the 17 factors compared between the two stocks.

How does iBio compare to Nkarta?

Nkarta (NASDAQ:NKTX) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Nkarta has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, iBio has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

In the previous week, Nkarta had 1 more articles in the media than iBio. MarketBeat recorded 6 mentions for Nkarta and 5 mentions for iBio. iBio's average media sentiment score of 0.98 beat Nkarta's score of 0.97 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 8.4% of Nkarta shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nkarta currently has a consensus price target of $11.33, indicating a potential upside of 270.37%. iBio has a consensus price target of $4.75, indicating a potential upside of 206.45%. Given Nkarta's higher probable upside, analysts plainly believe Nkarta is more favorable than iBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

iBio has higher revenue and earnings than Nkarta. iBio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.40	N/A
iBio	$400K	140.04	-$18.38M	-$0.58	N/A

Nkarta's return on equity of -29.75% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-29.75%	-23.43%
iBio	N/A	-64.97%	-54.58%

Summary

Nkarta beats iBio on 8 of the 15 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$58.19M	$751.85M	$4.27B	$12.20B
Dividend Yield	N/A	4.84%	6.10%	5.30%
P/E Ratio	-2.67	1.58	23.37	25.58
Price / Sales	140.04	117.64	157.54	78.84
Price / Cash	N/A	20.07	51.43	55.34
Price / Book	1.72	7.73	37.09	6.66
Net Income	-$18.38M	-$3.64M	$114.78M	$333.63M
7 Day Performance	-5.49%	3.68%	1.97%	-0.11%
1 Month Performance	-29.22%	48.73%	4.00%	3.94%
1 Year Performance	N/A	102.66%	16.86%	36.07%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	4.4267 of 5 stars	$1.55 -3.7%	$4.75 +206.5%	N/A	$58.19M	$400K	N/A	100	Earnings Report Upcoming Earnings
VYGR Voyager Therapeutics	2.7473 of 5 stars	$4.17 +6.9%	$16.50 +295.7%	+26.5%	$251.95M	$40.37M	N/A	100	News Coverage Earnings Report
FENC Adherex Technologies	3.923 of 5 stars	$7.18 +6.8%	$14.80 +106.1%	+4.5%	$248.00M	$44.64M	N/A	10
HRTX Heron Therapeutics	2.3828 of 5 stars	$1.31 +6.5%	$4.50 +243.5%	-50.3%	$247.12M	$154.90M	N/A	300	Earnings Report Analyst Forecast High Trading Volume
RNAC Cartesian Therapeutics	3.4318 of 5 stars	$8.34 +12.9%	$34.00 +307.7%	-17.5%	$245.03M	$2.80M	N/A	64	Positive News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. VYGR, FENC, HRTX, RNAC, and NKTX

How does iBio compare to Voyager Therapeutics?

Summary

How does iBio compare to Adherex Technologies?

Summary

How does iBio compare to Heron Therapeutics?

Summary

How does iBio compare to Cartesian Therapeutics?

Summary

How does iBio compare to Nkarta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. VYGR, FENC, HRTX, RNAC, and NKTX

How does iBio compare to Voyager Therapeutics?

Does the media prefer IBIO or VYGR?

Which has more risk and volatility, IBIO or VYGR?

Is IBIO or VYGR more profitable?

Which has higher earnings & valuation, IBIO or VYGR?

Do insiders & institutionals believe in IBIO or VYGR?

Do analysts recommend IBIO or VYGR?

Summary

How does iBio compare to Adherex Technologies?

Does the media prefer IBIO or FENC?

Which has more volatility & risk, IBIO or FENC?

Is IBIO or FENC more profitable?

Which has stronger earnings and valuation, IBIO or FENC?

Do institutionals & insiders believe in IBIO or FENC?

Do analysts recommend IBIO or FENC?

Summary

How does iBio compare to Heron Therapeutics?

Which has more volatility & risk, IBIO or HRTX?

Does the media prefer IBIO or HRTX?

Do institutionals & insiders believe in IBIO or HRTX?

Do analysts recommend IBIO or HRTX?

Which has stronger earnings and valuation, IBIO or HRTX?

Is IBIO or HRTX more profitable?

Summary

How does iBio compare to Cartesian Therapeutics?

Which has more risk & volatility, RNAC or IBIO?

Does the media favor RNAC or IBIO?

Do insiders and institutionals believe in RNAC or IBIO?

Do analysts recommend RNAC or IBIO?

Which has higher earnings & valuation, RNAC or IBIO?

Is RNAC or IBIO more profitable?

Summary

How does iBio compare to Nkarta?

Which has more risk & volatility, NKTX or IBIO?

Does the media favor NKTX or IBIO?

Do insiders and institutionals believe in NKTX or IBIO?

Do analysts recommend NKTX or IBIO?

Which has higher earnings & valuation, NKTX or IBIO?

Is NKTX or IBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools